Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group for 1.46 billion Swiss francs $1.8 billion , or 44.31 francs per share. Expected to close by the end of this year, the deal marks the South Korean company's entry into peptide therapeutics and is, by its own…
Samsung Biologics announced on Monday a public tender offer to acquire PolyPeptide Group of Switzerland for 1.46 billion Swiss francs in cash, approximately $1.8 billion. Stockholders would receive 44.31 Swiss francs per share. Samsung Biologics said the transaction is the largest biopharmaceutical M&A deal in South Korea's history, a characterization that comes from the company itself and is not independently verified.
The offer is Samsung Biologics' entry into peptide therapeutics , which it described as one of the fastest-growing segments in the biopharmaceutical industry. The target specializes in peptide-based active pharmaceutical ingredients APIs , the synthetic molecules at the center of GLP-1 obesity and diabetes drugs. Peptide therapeutics are medicines made from short chains of amino acids. The GLP-1 drugs work by mimicking a natural hormone to reduce appetite and regulate blood sugar, and demand for them has made peptide manufacturing capacity a strategic commercial asset.
PolyPeptide's board endorsed the offer after a strategic review. The transaction is expected to close at the end of this year. That timing is an expectation, not a confirmed outcome, and the announcement did not state the regulatory approvals or other conditions required for completion.
The consideration is entirely cash. Samsung Biologics is offering 44.31 Swiss francs per PolyPeptide share, valuing the company at 1.46 billion Swiss francs, or roughly $1.8 billion. An all-cash price has a specific meaning for shareholders: the value is fixed when the offer is made, it does not move with the buyer's stock price, and stockholders are paid in money rather than in shares they may not want to hold.
The offer follows a formal review of strategic options by PolyPeptide's board. Peter Wilden, Chairman of PolyPeptide Group: "After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today."
Wilden's endorsement is a statement from a party to the transaction, not an independent valuation. What it signals is that PolyPeptide's board intends to recommend that shareholders tender and is not seeking a competing auction.
Several terms of the deal have not been disclosed. The announcement does not specify a minimum share-acceptance threshold for the tender offer to be declared successful, it does not describe PolyPeptide's share structure or say whether large shareholders have already committed to tender, and it does not list the approvals that must be obtained. Public tender offers in Switzerland operate under the country's takeover regime, and the formal offer document that follows will ordinarily set out acceptance conditions, deadlines, and shareholder rights. Until that document appears, the year-end closing date is a target, not a binding commitment.
PolyPeptide Group was spun off from the global pharmaceutical company Ferring in 1996. Its headquarters are in Baar, Switzerland, and its operations span five countries: Sweden, Belgium, France, the United States, and India. The network covers R&D, development, and commercial manufacturing, meaning PolyPeptide can take a peptide from initial synthesis through scale-up, registration, and commercial supply.
Its record includes the development and production of more than 1,000 therapeutic peptides. That number is the core asset in this deal. Peptide APIs are not made the way antibodies are. Antibodies are recombinant proteins produced by living cells in large bioreactors. Peptides are built chemically, most commonly by solid-phase peptide synthesis , in which amino acids are coupled one at a time onto a solid resin support and the completed chain is then cleaved off, purified, and processed into a drug substance.
Each peptide has its own synthesis route, its own impurity profile, and its own analytical methods. Process knowledge accumulates in a company's chemists, its documentation, and its facility design. It is not bought off the shelf, and it takes years to assemble. The "more than 1,000 therapeutic peptides" figure captures something concrete: a library of validated processes, regulatory files, and the experience of scaling molecules from research quantities to commercial supply. For a contract manufacturer, that library is the product.
The geographic spread matters for the same reason. Commercial peptide production must meet the inspection standards of regulators in every market where the finished drug is sold. Sites in the United States and Europe carry regulatory history, operating permits, and trained workforces. A buyer that acquires those sites gains registered capacity in the world's largest pharmaceutical markets, which is different from building a new plant in one country and seeking approvals from scratch.
For Samsung Biologics, whose existing offerings center on antibody drugs and antibody-drug conjugates , this is a second manufacturing franchise. An antibody-drug conjugate is an antibody carrying a cytotoxic payload attached through a chemical linker, so conjugation chemistry is not foreign to the company. But peptide synthesis is a separate production system with its own equipment, its own starting materials, and its own quality control. The acquisition is a way to own that system whole rather than reconstruct it over years.
Peptides sit between small molecules and large biologics. They are larger and more structurally defined than conventional small-molecule drugs, yet far smaller and simpler than antibodies. Peptides can be designed to bind their targets with high specificity, and their breakdown products are ordinary amino acids that the body processes routinely. Their weakness is stability: unmodified peptides are degraded quickly by enzymes in the gut and the bloodstream. The drugs that reach the market therefore depend on chemical modification, such as attaching a fatty acid chain that binds albumin and extends the molecule's half-life, or cyclizing the peptide to resist enzymatic cleavage.
GLP-1 biology explains why this chemistry is commercially central. Glucagon-like peptide-1 is an incretin hormone , released from the gut after a meal. It binds receptors on pancreatic beta cells and stimulates insulin secretion, but in a glucose-dependent way: strongly when blood sugar is high, weakly when it is not. It also suppresses glucagon secretion, slows gastric emptying, and reduces appetite through receptors in the brain. A single drug that mimics GLP-1 therefore regulates blood sugar and lowers body weight at the same time, which is why the class has become the commercial center of the obesity and type 2 diabetes markets.
The chemical features that make GLP-1 drugs effective also make them difficult to manufacture at scale. The leading GLP-1 molecules carry modifications that improve their stability, and each added modification complicates the synthesis, extends the number of steps, and creates new impurities to characterize and control. This is why peptide manufacturing has not followed the cost curve of small-molecule drugs; it is a discipline of high-value, process-intensive production.
Manufacturing is where the economics bind. GLP-1 peptides are long by peptide standards, their purity requirements are exacting, and process-related impurities must be controlled to very low levels. Synthesis yields and purification costs scale poorly, which means capacity, not just demand, determines how many patients can be treated. Demand for these drugs has repeatedly tested the industry's peptide manufacturing capacity, and shortages of GLP-1 products have been a recurring feature of the market.
That is the core of Samsung Biologics' rationale. The company is not adding a peptide product to a portfolio; it is acquiring the capacity and the know-how to make peptide APIs in a market where capacity itself is the scarce resource. The all-cash consideration, 1.46 billion Swiss francs, is a measure of how durable that scarcity is expected to be.
Samsung Biologics said the acquisition is intended to diversify its portfolio by expanding into peptide therapeutics and to broaden its existing offerings, which center on antibody drugs and antibody-drug conjugates. The logic is direct: the fastest-growing drug class of the current cycle is built from peptides, and the company's existing platforms do not make them. Buying capacity is faster than building it, and buying PolyPeptide also imports process chemistry, regulatory files, and client relationships.
The deal expands Samsung Biologics' global footprint through PolyPeptide's network in Sweden, Belgium, France, the U.S., and India. For a contract manufacturer, geography is part of the offering. Pharmaceutical customers increasingly expect suppliers to serve multiple markets, to provide redundant capacity, and to support filings in the U.S. and Europe from sites that regulators already know. PolyPeptide's five-country network supplies that, and Samsung Biologics, already one of the world's largest contract manufacturers of biologic medicines, can now pair its antibody capacity with a peptide network.
The scale claim deserves scrutiny. Samsung Biologics says the transaction is the largest biopharmaceutical M&A deal in South Korea's history. The statement comes from the company and has not been independently verified. Deal-size comparisons across time depend on currency adjustments and on which transactions are counted, so the characterization should be treated as the buyer's framing rather than an established record.
What is clear is the direction of travel. A company with deep capital and a dominant position in biologics manufacturing has chosen peptides as its next platform. That choice reflects two judgments: that the peptide API market will keep growing, and that independent peptide manufacturers will remain scarce enough that buying one now, in cash, is the rational way in.
For peptide researchers, the change of ownership reshapes access to development and manufacturing capabilities. PolyPeptide has been a supplier of peptide synthesis, process development, and commercial manufacture to a broad range of partners. Its more than 1,000 therapeutic peptides represent projects across many clients and disease areas, and those relationships are part of what Samsung Biologics is paying for. Whether existing contracts continue with the same terms, the same sites, and the same teams has not been announced, and academic and biotech customers will want assurances on continuity during the integration window.
For clinicians and patients, the stakes run through GLP-1 supply. Availability of obesity and diabetes medicines has been limited by peptide manufacturing capacity as much as by demand. A well-capitalized owner of PolyPeptide's network could invest in capacity and improve security of supply. The opposite outcome is also possible, if integration shifts capacity, pricing, or priorities toward the new owner's internal programs. Peptide Atlas's databases track peptide therapeutics from early discovery through clinical trials and approved products, and the GLP-1 class is the clearest example of the field's move from a specialty niche to a standard treatment category in metabolic disease. This transaction is an industrial recognition of that move.
For the wider peptide field, the deal is a signal about industrial value. Peptides are not limited to metabolic disease; they are used across oncology, infection, and rare disease. The same synthesis and scale-up constraints apply, and the strategic logic that draws…
Peptides referenced: Glucagon, GLP-1.
Vendors referenced: Independent Peptide.
Related reading: GLP-1 Bridge program goes into effect; physicians seek accessible treatment options for obesity, Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide, Samsung Biologics to Acquire PolyPeptide in Record $2 Billion Deal, Samsung Biologics launches record $1.8 billion bid for PolyPeptide, targeting obesity drug market.